Drug intelligence / Profile preview

lipovirtide

Development stage: Phase 2
Lead developer: Shanxi Kangbao Biological Products
Modality: Peptides
Administration: Subcutaneous

Overview

Lipovirtide is a gp41 inhibitor, developed by Shanxi Kangbao Biological Product Co. Ltd., primarily for the treatment of HIV infections. It is a synthetic peptide designed to disrupt the HIV-1 fusion process by targeting the gp41 protein, similar to other fusion inhibitors like enfuvirtide. Lipovirtide is currently in Phase 2 clinical trials and has shown promise in combination with nucleoside drugs for treating HIV-infected patients.

Targets

HIV-1 gp41 NHR (HIV-1 gp41 N-terminal heptad repeat region)

Beyond the preview

Go deeper on lipovirtide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lipovirtide.

Explore the full profile